Trials show dupilumab effective, safe for moderate to severe AD
The SOLO 1 and SOLO 2 phase 3 trials of the human monoclonal anti-body dupilumab for the treatment of eczema/atopic dermatitis (AD) have...
Trials show dupilumab effective, safe for moderate to severe AD
Study casts doubt about link between eczema, cardiovascular disease
Stress levels before pregnancy could influence risk of eczema in offspring
Filaggrin deficiency’s ties to eczema clarified
Fine-fibre wool clothing appears better for childhood eczema than cotton
ACD statement aims to reduce ‘steroid phobia’
Prophylactic use of petrolatum could be cost-effective way to prevent AD
Air pollution may contribute to atopic dermatitis through activation of AhR transcription factor